Is It Time to Buy Biotech Stocks?
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
Viking Therapeutics ( VKTX ) Is Considered a Good Investment by Brokers: Is That True?
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings?
LLY eyes Q2 growth on Mounjaro and Zepbound momentum, but pricing pressure and rising competition test its edge.
This Biotech Stock Could Soar on Upcoming Clinical Data
This weight loss drugmaker may be significantly undervalued right now.
2 Beaten-Down Stocks With Incredible Upside Potential
Getting in on the ground floor with these companies might lead to superior returns.
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts
These biotech businesses look compelling for very different reasons.
Is Viking Therapeutics the Next Big Biotech Bet?
Explore the exciting world of Viking Therapeutics ( NASDAQ: VKTX ) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of Jul. ...
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.
Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare - And Trade Deal Optimism Boosts Markets Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare - And Trade Deal Optimism Boosts Markets - Cigna Group ( NYSE:CI ) , C3.ai ( NYSE:AI )
Benzinga examined the prospects for many investors' favorite stocks over the last week - here's a look at some of our top stories. Wall Street rallied as a wave of new trade deals - including agreements with Japan, Indonesia, and the Philippines - fueled optimism, pushing the S&P 500 and Nasdaq ...
Behind the Scenes of Viking Therapeutics's Latest Options Trends - Viking Therapeutics ( NASDAQ:VKTX )
Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics VKTX. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
Tesla Posts Downbeat Earnings, Joins Community Health Systems, Chipotle Mexican Grill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Community Health Sys ( NYSE:CYH ) , Chipotle Mexican Grill ( NYSE:CMG )
U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Thursday. Shares of Tesla, Inc. TSLA fell sharply in pre-market trading as the company reported weaker-than-expected second-quarter financial results after market close Wednesday.
Viking Therapeutics Posts Wider Q2 Loss
Viking Therapeutics ( NASDAQ:VKTX ) , a clinical-stage biopharmaceutical company focused on treatments for obesity and metabolic diseases, released results for its second quarter on July 23, 2025. The key takeaway from the update was a higher-than-expected net loss ( GAAP ) for Q2 2025, driven by ...
Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates - Viking Therapeutics ( NASDAQ:VKTX )
Viking Therapeutics reports a second-quarter loss of 58 cents per share, missing analyst estimates for a loss of 46 cents per share. Viking ends the quarter with $808 million in total cash, cash equivalents and short-term investments.
Viking ( VKTX ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, July 23, 2025 at 4:30 p.m. ETChief Executive Officer - Brian LianContinue reading ...
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Eli Lilly ( NYSE: LLY ) and Viking Therapeutics ( NASDAQ: VKTX ) have garnered considerable attention over the past year due to their solid clinical progress. However, these drugmakers have also lagged the market over the trailing-12-month period.
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.
3 Monster Stocks in the Making to Buy Right Now
Where can you find the next monster stocks? Check out the biotech space. It's not easy, but investors can sometimes find highly promising biotech stocks that are only in their early innings.Three Motley Fool contributors think they've identified monster stocks in the making.
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?
Investors seeking stocks that can put up dramatic gains in a short amount of time can find what they're looking for in the biotechnology industry. Investment bank analysts on Wall Street have tagged a pair of pre-revenue businesses with price targets that are miles above their current stock ...
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.
Is It Worth Investing in Viking Therapeutics ( VKTX ) Based on Wall Street's Bullish Views?
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Viking Therapeutics, Inc. ( VKTX ) Outperforms Broader Market: What You Need to Know
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $32.07, representing a +1.39% change from its previous close.
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
The Best Stocks to Invest $1,000 In Right Now
If you have $1,000 to invest right now, you may be wondering where to get started. You could buy stocks that are flying high and try to get in on the momentum, or you could look for bargains among stocks that have suffered in recent times.
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
Viking Therapeutics, Inc. ( VKTX ) Rises Higher Than Market: Key Facts
Viking Therapeutics, Inc. (VKTX) reached $31.29 at the closing of the latest trading day, reflecting a +2.93% change compared to its last close.
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Though you may think "tech stocks" when someone mentions growth, you actually can find growth stocks throughout a wide variety of industries. Even those like pharmaceuticals, often known for the steadiness of their earnings, may, through certain specialty areas, offer you the opportunity for ...
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Most investors have written off biotech stocks as a graveyard of broken dreams. While artificial intelligence ( AI ) captures Wall Street's imagination, the biotech industry -- once the crown jewel of innovation -- has been left for dead.But beneath the wreckage, Wall Street's sharpest funds are ...
Viking Therapeutics, Inc. ( VKTX ) Rises Higher Than Market: Key Facts
Viking Therapeutics, Inc. (VKTX) closed at $28.19 in the latest trading session, marking a +1.7% move from the prior day.
2 Beaten-Down Stocks With Massive Upside Potential
There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific issues that predate this year. Take, for instance, CRISPR Therapeutics ( NASDAQ: CRSP ) and Viking Therapeutics ( NASDAQ: VKTX ) , two mid-cap biotech companies that have ...
Is Viking Therapeutics ( VKTX ) a Buy as Wall Street Analysts Look Optimistic?
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
10 Incredible Growth Stocks Poised for Long-Term Gains
Growth stocks have been on a tumultuous ride in 2025. The confluence of geopolitical turmoil, high interest rates, the artificial intelligence ( AI ) superbuild, and valuation concerns has created dramatic volatility.While everyone obsesses over the "Magnificent Seven," a collection of ...
Got $200? 2 Biotech Stocks to Buy and Hold Forever
Some potential investors hesitate to get started on building an investment portfolio because they think they need thousands of dollars to grow wealth. But I've got good news for them and for you: You don't have to start out with a huge pile of cash to invest in stocks that may significantly add ...
Viking Therapeutics, Inc. ( VKTX ) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.52, representing a -5.86% change from its previous close.
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
Why This Weight Loss Drug Company's Stock Surged Today
Shares in biopharmaceutical company Viking Therapeutics ( NASDAQ: VKTX ) were up by 6.3% at 12:30 a.m. ET today. The move likely stems from the market digesting the previous day's news that Viking had initiated a phase 3 trial of its most promising program in its pipeline, namely VK2375, a ...
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735
Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.
3 Growth Stocks I'm Loading Up On
Growth stocks are having a moment. Several small- and mid-cap stocks have suddenly jumped 40% or more in the past 30 days.The catalyst? Investors are piling into innovative growth companies in response to the rapid pace of development of artificial intelligence ( AI ) , alongside the potential ...
What's Going On With Viking Therapeutics Stock On Wednesday? - Viking Therapeutics ( NASDAQ:VKTX )
Phase 3 VANQUISH program will enroll 5,600 adults across two obesity-focused studies over 78 weeks. Participants will receive weekly VK2735 injections at 7.5 mg, 12.5 mg, or 17.5 mg doses or placebo. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.
My 5 Favorite Dirt Cheap Stocks to Buy Right Now
Though indexes have rebounded, the first half of the year has been rocky for investors. The market had to digest a variety of uncertainties, from geopolitical problems to mixed economic data and the U.S. plan to tax imports.
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line.
Viking Therapeutics, Inc. ( VKTX ) Dips More Than Broader Market: What You Should Know
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $26.01, indicating a -1.03% shift from the previous trading day.
